Your browser doesn't support javascript.
loading
Antiphospholipid antibodies and the endothelium.
Meroni, P L; Raschi, E; Testoni, C; Tincani, A; Balestrieri, G.
Afiliação
  • Meroni PL; Allergy and Clinical Immunology Unit, Department of Internal Medicine, University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy. pierluigi.meroni@unimi.it
Rheum Dis Clin North Am ; 27(3): 587-602, 2001 Aug.
Article em En | MEDLINE | ID: mdl-11534262
The interaction between aPL (particularly anti-beta 2GPI antibodies) and endothelium does represent a potential pathogenetic mechanism for the thrombotic manifestations of the syndrome. The autoantibody-mediated EC activation probably plays a role in sustaining the appearance of a proadhesive, proinflammatory, and procoagulant phenotype. The heterogeneity of the APS clinical manifestations is likely linked to the varied effects that aPL can induce on ECs and to the different functions that ECs display depending on the anatomic localization.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Anticorpos Antifosfolipídeos / Endotélio Idioma: En Ano de publicação: 2001 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Anticorpos Antifosfolipídeos / Endotélio Idioma: En Ano de publicação: 2001 Tipo de documento: Article